News The latest developments in autism research.
Profiles Portraits of scientists who are making a mark on autism research.
Toolbox Emerging tools and techniques that may advance autism research.
Spotted A roundup of autism papers and media mentions you may have missed.
Opinion Conversations on the science of autism research.
Viewpoint Expert opinions on trends and controversies in autism research.
Columnists Dispatches from experts on various facets of autism.
Crosstalk Debates and conversations about timely topics in autism.
Reviews Exploring the intersection of autism and the arts.
Q&A Conversations with experts about noteworthy topics in autism.
Deep Dive In-depth analysis of important topics in autism.
Special Reports Curated collections of articles on special topics in autism.
Webinars Presentations by leading experts on their latest research.
Animation and data visualization by Nicholas Rapp
News

Despite setbacks, fragile X drugs file into clinical trials

by  /  30 November 2016

The road to treatments for fragile X syndrome is paved with solid facts and sound premises. But the syndrome — characterized by intellectual disability, hyperactivity, seizures and, often, autism — has so far resisted a pharmaceutical solution.

In the past several years, multiple fragile X treatments have undergone vetting in clinical trials1. So far, only one trial has shown improvement on the primary outcome measure — in that case, a clinician’s overall impression — but it was too small to be conclusive. Other trials are ongoing.

 

Fragile X syndrome stems from a mutation in a single gene called FMR1. This genetic cause distinguishes the syndrome from many other forms of autism, which typically have multiple genetic contributors. In theory, this genetic specificity should steer researchers toward effective treatments.

Yet FMR1 turns out to be the tip of the molecular iceberg underlying the condition: Its protein regulates thousands of other proteins in the cell. As a result, it is unclear what cellular pathways lead to the condition’s features.

Several of the treatments for fragile X syndrome block a receptor called mGluR5.

These treatments interfere with a pathway that stimulates excitatory signaling in the brain. Other candidates boost inhibitory signaling through a molecule known as gamma-aminobutyric acid (GABA) as a way to counteract excess excitatory activity.

Crystal ball:

These therapies have worked well in mouse models of the condition, but the mice don’t accurately mirror the condition in people. For example, mice lacking FMRI fail to show the cognitive deficits that people with fragile X syndrome do. As a result, researchers have had trouble determining which fragile X features to measure when they move a treatment into human trials.

In designing a trial, scientists need to specify a particular feature or ‘primary endpoint’ they aim to ameliorate. If this feature remains unmoved, the drug is unlikely to be approved — even if it eases other features of the condition.

So far, no treatment for fragile X syndrome has made a significant dent in its primary endpoint, although in some cases, a drug has improved other aspects of the syndrome.

Researchers have not given up, however. They are working on better ways to test the effects of drugs on people. They are also trying drug combinations and drugs paired with behavioral therapy.


References:
  1. Ligsay A. and R.J. Hagerman Intractable Rare Dis. Res. 5, 158-167 (2016) PubMed
close

Log in to your Spectrum Wiki account

Email Address:

Password:


close

Request your Spectrum Wiki account

Spectrum Wiki is a community of researchers affiliated with an academic or research institutions. To be considered for participation, please fill out this form and a member of our team will respond to your request.

Name:

Email Address:

Title and Lab:

Area of Expertise:

Comments: